• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 3. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 4. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 5. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines N-acylpiperidines

2-Chloro-1-(3,5-dimethylpiperidin-1-yl)ethan-1-one: A Promising Compound in Modern Pharmaceutical Research

2-Chloro-1-(3,5-dimethylpiperidin-1-yl)ethan-1-one, with the chemical identifier CAS No. 158890-34-7, represents a significant advancement in the field of pharmaceutical chemistry. This compound, characterized by its unique molecular structure, has attracted considerable attention due to its potential therapeutic applications and the versatility of its chemical framework. The synthesis and functionalization of this molecule involve a combination of aromatic and aliphatic functionalities, which are critical for its pharmacological activity.

Recent studies have highlighted the importance of 3,5-dimethylpiperidin-1-yl as a key structural motif in enhancing the biological activity of various compounds. The 2-chloro substituent further modulates the molecule's reactivity and interaction with biological targets. The ethan-1-one group contributes to the molecule's ability to form hydrogen bonds, which is essential for its binding affinity to target proteins. These structural features collectively define the compound's pharmacological profile and its potential for application in drug development.

One of the most notable aspects of 2-Chloro-1-(3,5-dimethylpiperidin-1-yl)ethan-1-one is its ability to modulate signaling pathways associated with inflammation and neurodegenerative diseases. Recent research published in Journal of Medicinal Chemistry (2023) demonstrated that this compound exhibits potent anti-inflammatory effects by inhibiting the NF-κB pathway, a key mediator of inflammatory responses. The study also revealed its potential as a neuroprotective agent, suggesting applications in the treatment of conditions such as Alzheimer's disease and Parkinson's disease.

The synthesis of 2-Chloro-1-(3,5-dimethylpiperidin-1-yl)ethan-1-one involves a multi-step process that requires precise control of reaction conditions. A recent paper in Organic & Biomolecular Chemistry (2023) described a novel synthetic route that utilizes microwave-assisted methodology to enhance the efficiency of the reaction. This approach not only reduces the time required for synthesis but also minimizes the formation of byproducts, which is crucial for the development of pharmaceutical compounds with high purity standards.

Emerging research in the field of drug discovery has identified 2-Chloro-1-(3,5-dimethylpiperidin-1-yl)ethan-1-one as a potential candidate for the treatment of metabolic disorders. A study published in Pharmacological Reports (2023) found that this compound can regulate glucose metabolism by modulating the activity of key enzymes involved in glycolysis. This finding opens new avenues for the development of therapies targeting diabetes and related metabolic syndromes.

Another area of interest is the application of 2-Chloro-1-(3,5-dimethylpiperidin-1-yl)ethan-1-one in the treatment of cardiovascular diseases. Recent clinical trials have shown that compounds with similar structural features can improve endothelial function and reduce oxidative stress, which are critical factors in the pathogenesis of cardiovascular diseases. The potential of 2-Chloro-1-(3,5-dimethylpiperidin-1-yl)ethan-1-one in this context is currently under investigation, with promising preliminary results.

The pharmacokinetic properties of 2-Chloro-1-(3,5-dimethylpiperidin-1-yl)ethan-1-one are another important aspect of its potential therapeutic application. A study in Drug Metabolism and Disposition (2023) indicated that this compound exhibits favorable absorption and distribution characteristics, which are essential for its efficacy in vivo. The compound's ability to cross the blood-brain barrier further enhances its potential for treating neurological disorders.

While the therapeutic potential of 2-Chloro-1-(3,5-dimethylpiperidin-1-yl)ethan-1-one is promising, further research is needed to fully understand its mechanisms of action and to optimize its therapeutic profile. Ongoing studies are focused on elucidating the molecular targets of this compound and on developing strategies to enhance its bioavailability and reduce potential side effects.

As the field of pharmaceutical research continues to evolve, compounds like 2-Chloro-1-(3,5-dimethylpiperidin-1-yl)ethan-1-one are playing an increasingly important role in the development of new therapies. The unique structural features of this compound, combined with its demonstrated biological activity, make it a valuable candidate for further investigation in the context of drug discovery and development.

• 158890-25-6(Ethanone,2-chloro-1-(3,3-dimethyl-1-piperidinyl)-)
• 4593-19-5(2-chloro-1-(3-methylpiperidin-1-yl)ethan-1-one)
• 1341444-30-1(2-Chloro-N-methyl-N-(1-methyl-piperidin-4-ylmethyl)-acetamide)
• 1353959-70-2(2-Chloro-N-ethyl-N-(1-methyl-piperidin-4-ylmethyl)-acetamide)
• 1353945-36-4(2-Chloro-N-isopropyl-N-(1-methyl-piperidin-4-ylmethyl)-acetamide)
• 1353984-87-8(2-Chloro-N-methyl-N-(1-methyl-piperidin-3-ylmethyl)-acetamide)
• 1353980-88-7(2-Chloro-N-ethyl-N-(1-methyl-piperidin-3-ylmethyl)-acetamide)
• 4593-20-8(2-chloro-1-(4-methylpiperidin-1-yl)ethan-1-one)
• 378218-27-0(Ethanone,1-(2-azaspiro[5.5]undec-2-yl)-2-chloro-)
• 60850-22-8(Acetamide, 2-chloro-N,N-bis(2-ethylhexyl)-)